Atlas/ Growth-Hormone Axis & Secretagogues/ GHRH Analogs · GH / IGF-1 Secretagogues/ CJC-1295
Reading depth · audience layer
Class 09 · Growth-hormone axis · Synthetic GHRH(1-29) analog · GH / IGF-1 secretagogue signal

CJC-1295the long-acting GHRH analog · growth-hormone secretagogue

A synthetic peptide that mimics the body's own growth-hormone trigger (GHRH), telling the pituitary gland to release more of your growth hormone in its natural pulses rather than injecting GH directly. It exists in two forms: a short-acting one (No-DAC / Mod GRF 1-29, lasting about 30 minutes) and a long-acting one (with DAC) that latches onto a blood protein and keeps working for roughly a week per injection. In a small human trial it raised growth hormone 2–10× and IGF-1 1.5–3× for days. It has never been approved as a drug anywhere, its development was discontinued in 2007, and it is banned in sport by WADA. Everything below the Phase-I evidence line is a hypothesis built on early-stage human data and clinic practice patterns — not validated prescribing.

A tetrasubstituted synthetic analog of growth-hormone-releasing hormone, GHRH(1-29), developed by ConjuChem Biotechnologies. Four amino-acid substitutions (D-Ala², Gln⁸, Ala¹⁵, Leu²⁷) confer protease/DPP-IV resistance; the DAC variant adds a C-terminal maleimidopropionyl-lysine "Drug Affinity Complex" that covalently binds Cys34 of serum albumin, extending plasma half-life from minutes to 5.8–8.1 days. The pivotal Phase I program (Teichman 2006, JCEM, n=21 healthy adults) showed dose-dependent 2–10× GH and 1.5–3× IGF-1 elevation lasting 9–11 days from a single dose, up to 28 days after multiple doses, with pulsatility preserved. Clinical development was discontinued in 2006–2007; no indication has ever received regulatory approval, and the FDA classifies CJC-1295 as a developmental drug ineligible for 503A compounding.

CJC-1295 (DAC:GRF; CAS 446262-90-4 with DAC / 863288-34-0 No-DAC; MW 3,647 Da DAC / 3,368 Da No-DAC) is a 29-residue GHRH(1-29) analog rather than a single-pathway ligand. The C-terminal maleimidopropionyl-lysine moiety thioetherifies albumin Cys34 within minutes of SC injection, converting the ~3.4 kDa peptide into an effective ~69 kDa circulating depot (t½ 5.8–8.1 d in humans vs. ~7 min for native GHRH). The albumin-bioconjugate mechanism and GRF-receptor activation on the anterior pituitary were first established in rats (Endocrinology 2005, PMID 15817669). GHRHR agonism (class B secretin-family GPCR) recruits Gαs → adenylyl cyclase → cAMP → PKA → CREB phosphorylation and voltage-gated Ca²⁺-channel-driven somatotroph exocytosis; endogenous somatostatin preserves pulsatility. Downstream JAK2/STAT5b-mediated hepatic IGF-1 synthesis activates IGF1R/PI3K/Akt/mTOR and MAPK/ERK — underpinning both the anabolic utility and the theoretical oncogenic concern of sustained IGF-1 elevation. Overall clinical GRADE: LOW–MODERATE (Phase I/II only; no Phase III).

1 Phase I RCT Pivotal human PK/PD · n=21 · Teichman 2006 · no Phase III
5.8–8.1 d Plasma half-life · DAC form (human PK) · ~30 min No-DAC
2–10× GH Dose-dependent GH rise · IGF-1 1.5–3× · up to 28 d
29 AA GHRH(1-29) analog · 4 substitutions + DAC · ~3,647 Da
Status
Unapproved · developmental drug · not 503A-compoundable
Open dose calculator
Routes
Subcutaneous (primary) · IM (rare) · intranasal (anecdotal)
Originator
ConjuChem Biotechnologies · Montreal · early 2000s
WADA status
Prohibited · S2 · in- & out-of-competition
01 · At a glance

Key facts & headline data.

CJC-1295 occupies an unusual position: it has the strongest pharmacokinetic human dataset of almost any "research peptide" in this atlas — a real, published, placebo-controlled Phase I program — yet no completed Phase III, no approved indication, an abandoned development history, and a regulatory status complicated by its classification as a developmental drug. Every body-composition or anti-aging benefit claim remains unproven; the GH/IGF-1 elevation is real but is a biomarker, not a validated clinical outcome.

🧬
Origin · development
ConjuChem · ~2004
Developed by ConjuChem Biotechnologies (Montreal) using their Drug Affinity Complex (DAC) albumin-binding technology in the early-to-mid 2000s. Phase I (GH deficiency) and Phase II (HIV lipodystrophy) programs were both discontinued in March 2007. The albumin-bioconjugate GRF analog was first characterized in rats in 2005.
🧪
Total human evidence
~n=33 + halted PII
Three published human studies with complete data (Teichman 2006 PK/PD n=21; Ionescu 2006 pulsatility n=12; Sackmann-Sala 2009 proteomics subset). A Phase II HIV-lipodystrophy trial (NCT00267527, n=192 enrolled) was halted in July 2006 after a participant death deemed unrelated to drug — results never published. No Phase III exists.
⏱️
Half-life (DAC vs No-DAC)
5.8–8.1 d / ~30 min
The DAC variant's covalent albumin binding gives a human plasma half-life of 5.8–8.1 days, enabling once-weekly dosing; the No-DAC form relies on DPP-IV resistance alone for a ~30-minute half-life, requiring daily/BID dosing. This single design choice defines the two completely different dosing models.
📈
Pharmacodynamic effect
GH 2–10× · IGF-1 ↑28 d
A single SC dose produced dose-dependent 2–10× GH and 1.5–3× IGF-1 elevation lasting 9–11 days; after multiple doses IGF-1 remained above baseline up to 28 days, with a cumulative effect and preserved pulsatility. Reproducible and dose-dependent — but a surrogate, not a clinical endpoint.
💉
Proposed human dose
1–2 mg/wk · 100–300 µg/d
Practice-pattern dosing: DAC form 1–2 mg SC once weekly; No-DAC form 100–300 µg SC 1–3× daily, most often combined with ipamorelin. Phase I studied single doses of 30–120 µg/kg; 30–60 µg/kg were well tolerated, GI adverse events appeared at 100 µg/kg.
📋
Regulatory status (May 2026)
Developmental drug · WADA S2
Not FDA-approved. Among the first five peptides removed from FDA 503A Category 2 (Sept 2024), but FDA/PCAC recommended against adding it to the 503A bulks list; it is classified as a developmental drug and remains ineligible for compounding. Prohibited in sport under WADA S2.
02 · Mechanism of action

How a long-acting GHRH analog works.

CJC-1295 doesn't add growth hormone — it tells your own pituitary to make more. It copies GHRH, the natural "release growth hormone" signal, but is re-engineered to survive far longer in the body. The DAC version grabs onto albumin (the most abundant blood protein) so a single shot keeps gently nudging the pituitary for about a week. Crucially, it raises the height and floor of your natural GH pulses while leaving the rhythm intact — unlike injecting GH directly, which flattens that rhythm. The extra GH then drives the liver to make IGF-1, the hormone behind most of GH's effects on muscle, fat, and recovery.

Six mechanistically linked arms. First — high-affinity agonism at the GHRH receptor (GHRHR), a class B GPCR on anterior-pituitary somatotrophs, amplifying GH pulse amplitude and trough levels. Second — DAC albumin binding: the maleimidopropionyl-lysine linker covalently bonds albumin Cys34, transforming the peptide into a ~69 kDa depot and extending t½ to 5.8–8.1 days. Third — the canonical Gαs → adenylyl cyclase → cAMP → PKA → CREB cascade with Ca²⁺-driven exocytosis. Fourth — downstream hepatic IGF-1 synthesis (1.5–3× for 9–28 days). Fifth — DPP-IV resistance from the D-Ala² substitution. Sixth — preservation of pulsatility, because endogenous somatostatin continues to brake GH release even under sustained GHRH stimulation.

CJC-1295 is a GHRHR agonist whose distinguishing pharmacology is kinetic, not target-novel. Robinson/ConjuChem (Endocrinology 2005, PMID 15817669) established that hGRF(1-29)–albumin bioconjugates activate the pituitary GRF receptor in rats and identified CJC-1295 as the long-lasting lead. The maleimide–thiol reaction with albumin Cys34 is essentially irreversible under physiological conditions, creating a circulating depot that re-engages GHRHR across multiple endogenous pulse windows. Downstream, GH binds hepatic GHR → JAK2/STAT5b → IGF-1 transcription; circulating IGF-1 activates IGF1R tyrosine kinase → PI3K/Akt/mTOR and MAPK/ERK — the same mitogenic cascade epidemiologically linked to several cancers, which is the mechanistic basis for the oncology caution. No human receptor-occupancy/EC50 dataset for the engineered analog has been published.

B
🎯

GHRH receptor agonism (primary)

The core mechanism. CJC-1295 is a high-affinity agonist at the GHRH receptor on anterior-pituitary somatotrophs, preserving pulsatile GH secretion while amplifying both pulse amplitude and trough levels. In healthy adults this produced dose-dependent 2–10× GH elevation lasting ≥6 days.
Clinical significance: Amplifying endogenous pulsatile GH — rather than imposing tonic exogenous GH — is the central therapeutic rationale. Supraphysiological flat GH (as with rhGH) is associated with greater insulin resistance and acromegalic effects; pulse amplification is theoretically gentler, though this advantage has never been demonstrated on a clinical endpoint.
Molecular detail: GHRHR is a class B (secretin-family) seven-transmembrane GPCR. CJC-1295 engages both the large extracellular N-terminal domain and the transmembrane helical bundle, recruiting Gαs → adenylyl cyclase. No published Ki/EC50 exists for the engineered analog in human tissue, so a target-engagement PK/PD model cannot currently be constructed.
B
🧲

DAC albumin-binding · PK extension

The defining feature of the DAC variant. A maleimidopropionyl (MPA) linker at the C-terminus forms a covalent thioether bond with Cys34 of serum albumin within minutes of injection, turning the ~3.4 kDa peptide into an effective ~69 kDa albumin–peptide conjugate. This blocks DPP-IV cleavage and renal filtration, extending half-life to 5.8–8.1 days.
Clinical significance: The 8-day half-life enables once-weekly dosing but also means that any adverse effect — water retention, IGF-1 over-elevation — persists for over a week after the last dose and cannot be rapidly reversed. This is the single most important practical difference from short-acting GHRH analogs.
Molecular detail: The maleimide–thiol reaction is essentially irreversible at physiological pH. Albumin functions as a circulating depot; as albumin–CJC-1295 slowly turns over, the peptide re-engages GHRHR across multiple endogenous GH-pulse windows. The bioconjugate strategy and receptor activation were validated in rats before human translation.
P

Adenylyl cyclase · cAMP · PKA cascade

Once bound, GHRHR activation via Gαs stimulates adenylyl cyclase, raising intracellular cAMP, activating PKA, opening voltage-gated calcium channels, and triggering exocytosis of GH-containing secretory granules. This is the established GHRH signal-transduction route applied to the engineered analog.
Clinical significance: Because the secretory step depends on existing somatotroph GH stores and intact downstream machinery, CJC-1295 cannot release GH a pituitary cannot make — a relevant limit in severe pituitary disease, and the reason it is a secretagogue, not a replacement.
Molecular detail: PKA phosphorylates CREB at Ser133, activating CRE-mediated transcription of the GH1 gene; PKA simultaneously potentiates L-type Ca²⁺ channels, and the resulting [Ca²⁺]i rise is the direct trigger for granule exocytosis. This pathway is drawn from general GHRH molecular pharmacology, not CJC-1295-specific cell studies — hence grade P.
B
🫀

IGF-1 axis activation (downstream)

The GH released downstream travels to the liver and drives IGF-1 production — the mediator of most of GH's body-composition and anabolic effects. Clinical studies show 1.5–3× IGF-1 elevation lasting 9–11 days after a single dose, and up to 28 days after multiple doses.
Clinical significance: Serum IGF-1 is the practical pharmacodynamic marker for CJC-1295 — the one biomarker actually validated in the Phase I program — and the safety governor: IGF-1 driven far above the age-adjusted reference range is the trigger for de-escalation or stopping.
Molecular detail: GH binds hepatocyte GHR → JAK2/STAT5b → IGF-1 gene transcription. Circulating IGF-1 binds IGF1R (receptor tyrosine kinase) → PI3K/Akt/mTOR and MAPK/ERK, mediating protein synthesis, lipolysis, and mitogenic/anti-apoptotic effects — the latter the basis of the theoretical tumor-promotion concern.
C
🛡️

DPP-IV resistance (enzymatic stability)

Native GHRH(1-29) is inactivated within minutes by dipeptidyl peptidase-IV (DPP-IV), which cleaves after the Ala at position 2. The D-Ala² substitution in CJC-1295 confers intrinsic DPP-IV resistance, extending the No-DAC half-life from ~7 minutes to ~30 minutes — and providing the stable backbone that the DAC further extends.
Clinical significance: This is why the No-DAC form ("Mod GRF 1-29") is usable at all without the DAC. Even so, the ~30-minute half-life means No-DAC must be dosed daily-to-BID and is nearly always paired with a GHRP for a clinically meaningful pulse.
Molecular detail: DPP-IV (CD26) is a serine protease that cleaves N-terminal dipeptides after Pro/Ala at position 2; the D-stereoisomer at Ala² sterically and electronically prevents recognition. The additional Gln⁸, Ala¹⁵, and Leu²⁷ substitutions reduce susceptibility to other proteases (trypsin-like and chymotrypsin-like cleavage).
B
🌊

GH pulsatility preservation

Unlike exogenous rhGH, CJC-1295 preserves the body's natural GH rhythm of peaks and troughs. Even during continuous GHRH stimulation from the DAC form, endogenous somatostatin continues to periodically inhibit pituitary GH release, maintaining pulsatile secretion (Ionescu & Frohman 2006).
Clinical significance: Preserved pulsatility is the headline safety argument for GHRH analogs over direct GH: tonic supra-physiological GH is more strongly tied to insulin resistance and acromegalic change. CJC-1295 amplifies trough GH ~7.5× and mean GH 2–10× while keeping the peak-to-trough rhythm.
Molecular detail: Intact hypothalamic somatostatin (SRIF) neurons cyclically suppress somatotroph responsiveness, gating the amplified GHRH signal into discrete pulses rather than a flat elevation. This is the mechanistic distinction from rhGH and the reason the molecule was pursued as a more physiologic GH therapy.
💉
Dose SC
DAC t½ ~8 d
🧲
Albumin
depot (DAC)
🎯
GHRHR
(class B GPCR)
cAMP · PKA
CREB · Ca²⁺
🌊
GH pulse
(amplified)
🫀
Hepatic
IGF-1
🧱
Anabolism
(IGF1R)
03 · Dosing protocols & models

Protocol-specific dosing architecture.

This is a speculative, hypothesis-driven dosing engine layered on top of (1) the Phase I ascending-dose data (single doses 30–120 µg/kg; weekly/biweekly multiple-dose arms), and (2) current human practice-pattern ranges — DAC 1–2 mg/week, No-DAC 100–300 µg/day — that are not from a validated prescribing label. No FDA-approved CJC-1295 dose exists for any indication. The architecture mirrors how clinicians titrate biologics and is intended as a base for protocol critique and research design, not validated prescribing. CJC-1295 is unique among atlas peptides in running on two completely different dosing models: a once-weekly milligram model (DAC) and a daily microgram model (No-DAC). Each protocol below is built to the same skeleton: starting dose, escalation cadence, dose ladder, maintenance target, cycle structure, reconstitution math, monitoring overlay, and explicit evidence grade.

Important · regulatory status & evidence ceiling CJC-1295 is not FDA-approved for any human indication in any jurisdiction, and its development was discontinued in 2007. It was among the first five peptides removed from FDA 503A Category 2 (Sept 2024), but FDA/PCAC recommended against adding it to the 503A bulks list; it is classified as a developmental drug and remains ineligible for compounding. It is prohibited in sport under WADA S2 (peptide hormones / growth factors), in- and out-of-competition. All dose ladders, biomarker thresholds, and titration rules below carry evidence grade D (practice-pattern) or P (preclinical/mechanistic extrapolation) and must not be read as clinical guidelines. Use only under IRB-approved research protocols or physician-supervised informed-consent settings, with verified product source.
PK note · why the two forms dose so differently The DAC variant's covalent albumin binding gives a human half-life of 5.8–8.1 days — long enough that a single weekly dose sustains GH/IGF-1 elevation across the whole interval, with IGF-1 staying above baseline up to 28 days after repeated dosing. The No-DAC form ("Mod GRF 1-29") relies on the D-Ala² substitution alone for a ~30-minute half-life, so it is dosed daily-to-BID and is essentially a short pulse-generator. The 8-day DAC half-life is a double-edged feature: it cannot be rapidly reversed, so any over-elevation of IGF-1 or fluid retention persists for more than a week after the last injection — titrate the DAC form slowly and confirm IGF-1 before each escalation. The No-DAC form is far more forgiving but rarely produces a meaningful sustained IGF-1 rise on its own, which is why it is almost always combined with a GHRP (ipamorelin).
CJC-1295 with DAC — Once-Weekly Protocol (Hypothetical)
SC · 1–2 mg once weekly · 8–12 wk cycle · practice-pattern
Grade D
Indication framing
GH/IGF-1 elevation for body composition, recovery, or somatopause-type research use. The weekly model is grounded in the Phase I finding that a single dose elevates IGF-1 for 9–11 days, so a weekly interval keeps IGF-1 continuously above baseline.
Starting dose
1,000 µg (1 mg) SC once weekly. Begin at the low end given the 8-day half-life and the inability to rapidly reverse an over-shoot.
Escalation cadence
Assess IGF-1 at week 4. If IGF-1 is <1.5× baseline (or still low-normal for age) and well tolerated → increase to 2 mg/week. Do not escalate on symptoms alone — confirm the biomarker first.
Dose ladder
1 mg/week → 1.5 mg/week → (cap) 2 mg/week. Above 2 mg/week adds IGF-1-driven risk without established benefit and should be flagged as off-protocol "experimental mode."
Maintenance target
1–2 mg SC once weekly, titrated to keep IGF-1 in the upper end of the age-adjusted reference range (≈1.2–2.0× baseline), never above 2.5× ULN.
Cycle structure
8–12 weeks on, then a 4–8 week washout. Because the half-life is 8 days, allow ≥2 weeks of clearance before interpreting an off-cycle IGF-1.
Reconstitution & injection
Typical 2 mg vial + 2 mL bacteriostatic water → 1,000 µg/mL = 10 µg/unit (U-100). 1 mg = 100 units (1.0 mL); 2 mg = the whole vial. 29–31 G insulin syringe, SC, rotate sites. Roll — don't shake. Refrigerate reconstituted product 2–8 °C, protect from light, avoid freeze-thaw. Use the calculator below for any vial/dose combination.
Monitoring overlay
IGF-1 at baseline, 4 wk, 12 wk (the one validated PD marker); fasting glucose and HbA1c if any diabetes risk; injection-site inspection. IGF-1 is the validated CJC-1295 marker; the glucose/HbA1c thresholds are borrowed from GH research, not BPC- or CJC-validated.
PK heuristic note
Phase I single doses spanned 30–120 µg/kg; 30–60 µg/kg were well tolerated (≈2.25–4.5 mg for a 75 kg adult), GI adverse events emerged at 100 µg/kg. The 1–2 mg/week practice band sits below the well-tolerated single-dose ceiling but is given repeatedly — cumulative IGF-1 effect is the dose-limiting variable, not peak GH.
⚠ Long half-life cannot be reversed The 5.8–8.1-day half-life means side effects (water retention, paresthesia, IGF-1 over-elevation) persist for >1 week after the last dose and cannot be rapidly undone. Titrate slowly, confirm IGF-1 before each step, and never stack with exogenous GH or IGF-1 LR3 (see hard-constraint note). Product quality is the dominant practical hazard — require HPLC ≥98% purity, sterility, endotoxin limits, and MS identity confirmation.
CJC-1295 No-DAC (Mod GRF 1-29) — Daily / BID Protocol (Hypothetical)
SC · 100–300 µg/day · 1–2× daily · 8 wk on / 8 wk off · practice-pattern
Grade D
Indication framing
Short-pulse GH stimulation favoring the natural rhythm. The ~30-minute half-life means each dose is a discrete pulse, not a sustained level — closest in spirit to physiologic GHRH. Standalone No-DAC produces only a modest GH response; it is most often used as a base for a GHRP combination (see next tab).
Starting dose
100 µg SC once daily, pre-bed and fasted. The pre-bed timing aligns with the largest natural nocturnal GH pulse.
Escalation cadence
Increase by 50 µg every 2 weeks toward the target band, gated on tolerability and (where measured) IGF-1 trend.
Dose ladder
100 µg/day → 150 → 200 → 250 → (maintenance) 200–300 µg/day. May split as BID (pre-workout + pre-bed) at the higher end.
Maintenance target
200–300 µg/day, once daily pre-bed or BID. The 300 µg "saturation dose" reflects the practice-pattern view that a single SC injection meaningfully stimulates the pituitary up to roughly this amount.
Cycle structure
8 weeks on / 8 weeks off; a 5-days-on / 2-days-off pattern within the cycle is a common practice-pattern convenience, not evidence-based.
Reconstitution & injection
5 mg vial + 2 mL BAC water → 2,500 µg/mL; 200 µg = 8 units (0.08 mL), 300 µg = 12 units. Alternatively 10 mg + 3 mL → 3,333 µg/mL. SC, rotate sites; same storage/handling.
Timing note
Inject fasted (≥45 min away from food) — dietary carbohydrate and fat raise insulin/somatostatin tone and blunt the GH pulse.
Monitoring overlay
IGF-1 at baseline and the 8-week mark; injection-site inspection. Standalone No-DAC frequently shows only a small IGF-1 change — interpret a flat IGF-1 as expected, not necessarily as non-response.
Why so different from DAC
With t½ ~30 min, there is no steady-state or trough concept — each injection is a pulse. PK-guided dosing is meaningless; cadence reflects "pulse coverage," not measured kinetics. This is the mirror image of the DAC model's sustained depot.
No-DAC + Ipamorelin — Dual-Pathway Stack (Most Common Clinical Use)
SC · 200–300 µg each · 1–3× daily · 8–16 wk · practice-pattern + mechanistic synergy
Grade D / C
Agents & rationale
CJC-1295 No-DAC 200 µg + Ipamorelin 200–300 µg in the same syringe. GHRH analog + GHRP act on complementary pituitary pathways (Gs/cAMP from GHRHR + Gq/IP3/Ca²⁺ from GHSR1a); the combination produces 2–5× more GH than either agent alone, and ipamorelin uniquely does not raise cortisol or prolactin.
Starting dose
200 µg of each, once daily pre-bed, fasted. This is the canonical "CJC/Ipa" starting point.
Escalation cadence
May increase to 300 µg of each at 4–6 weeks if well tolerated, or add a second/third daily dose (pre-workout, mid-day) for a more GH-pulse-rich pattern.
Dose ladder
200/200 µg QD → 300/300 µg QD → 200–300 µg each BID–TID. Keep each component at the saturation dose rather than pushing one component very high.
Maintenance target
200–300 µg of each, 1–3× daily, timed to natural pulse windows (pre-bed essential; pre-workout optional).
Cycle structure
8–16 weeks on / 4–8 weeks off. The longer "on" window than DAC reflects the gentler, reversible kinetics of the short-acting pair.
Reconstitution & injection
Each peptide reconstituted separately (5 mg vial + 2 mL BAC = 2,500 µg/mL) then drawn together; or a pre-blended vial. 200 µg of a 2,500 µg/mL solution = 8 units. SC, rotate sites.
Monitoring overlay
IGF-1 baseline + 8 wk; fasting glucose if metabolic risk; watch for additive water retention. No human RCT exists for this specific combination dose — the synergy rationale is mechanistic (grade C), the dose is practice-pattern (grade D).
Mechanistic synergy
The GHRH-analog arm raises the GH pulse ceiling while the GHRP arm both adds a ghrelin-receptor pulse and suppresses somatostatin tone — the two effects multiply rather than add, which is the basis for the 2–5× combined GH response reported across GHRH+GHRP studies.
⚠ Most-used, still unproven The CJC/Ipamorelin stack is the single most common real-world CJC-1295 use, but there is no combination RCT for this exact regimen and no long-term combination safety data. Additive fluid retention and the general GH-axis cautions (glucose, IGF-1 over-elevation) apply. Ipamorelin is the preferred GHRP partner precisely because it does not raise cortisol/prolactin — substituting GHRP-6 changes the side-effect profile (next tab).
DAC + GHRP-6 — Aggressive Pulse Stack (Hypothetical)
SC · DAC 1–2 mg/wk + GHRP-6 100–300 µg 2–3×/day · 8–12 wk · practice-pattern
Grade D / C
Agents & rationale
CJC-1295 DAC 1–2 mg/week + GHRP-6 100–300 µg 2–3×/day. GHRP-6 adds a ghrelin-receptor GH pulse on top of the sustained GHRH baseline from the DAC form. In preclinical models, GHRP-6 + CJC-1295 DAC significantly increased GH/IGF-1 without raising prolactin compared with GHRP-6 alone.
Starting dose
DAC 1 mg/week + GHRP-6 100 µg 2×/day; titrate GHRP-6 upward before increasing the DAC dose.
Dose ladder
GHRP-6 100 → 200 → 300 µg per dose, 2–3×/day; DAC 1 → 2 mg/week gated on IGF-1.
Cycle structure
8–12 weeks on / 4–8 weeks off. The DAC's 8-day clearance governs the washout.
Reconstitution
DAC 2 mg + 2 mL BAC = 1,000 µg/mL (1 mg = 100 units). GHRP-6 reconstituted separately; 200 µg of a 2,500 µg/mL solution = 8 units. Inject fasted.
Monitoring overlay
IGF-1 baseline/4 wk/12 wk; appetite and weight (GHRP-6 strongly stimulates hunger via ghrelin); fasting glucose; consider prolactin if symptoms arise (GHRP-6 may raise it, unlike ipamorelin).
Key caution
GHRP-6 produces larger GH pulses than ipamorelin but at the cost of significant appetite stimulation and possible cortisol/prolactin elevation — less suitable for patients with obesity or metabolic syndrome.
⚠ Greater side-effect load than the ipamorelin stack GHRP-6's strong ghrelin-mediated hunger and potential cortisol/prolactin elevation make this the less-preferred GHRP pairing for most clinical contexts. Reserve for research settings where the larger GH pulse is specifically wanted, and counsel on appetite effects.
Low-Dose / Somatopause Support (Experimental Wellness)
SC · DAC 500–1,000 µg/wk OR No-DAC 100 µg/day · conservative · opt-in only
Grade D
Indication framing
The weakest-evidenced use case — age-related GH decline ("somatopause") with no objective deficiency. Treat as opt-in "experimental wellness mode" with bright warnings; there is no defined target to titrate toward beyond keeping IGF-1 mid-range.
Conservative band
DAC 500–1,000 µg once weekly or No-DAC 100 µg/day — deliberately the low end of every practice range.
Escalation cadence
Generally no escalation for non-deficiency use. Hold at the conservative band; discontinue if no clear subjective benefit by 8–12 weeks. Do not chase IGF-1 upward without a deficiency diagnosis.
Dose ceiling
Crossing into 2 mg/week DAC or 300 µg/day No-DAC reclassifies the use as performance/indication-driven, not "wellness," and should carry the full monitoring overlay.
Cycle structure
8–12 weeks on, then a break. Reassess IGF-1 and symptoms off-cycle before resuming.
Reconstitution
DAC 2 mg + 2 mL = 1,000 µg/mL (500 µg = 50 units). No-DAC 5 mg + 2 mL = 2,500 µg/mL (100 µg = 4 units).
Monitoring overlay
IGF-1 + fasting glucose at baseline and end-of-cycle; keep IGF-1 within the age-adjusted reference range, never supraphysiologic. Counsel honestly that anti-aging GH-axis use has no outcome evidence and a real long-term IGF-1/cancer-signal caution.
⚠ Lowest-evidence use case There is no outcome evidence that raising GH/IGF-1 in non-deficient adults improves healthspan, and chronic IGF-1 elevation carries a theoretical tumor-promotion signal. This panel exists to model conservative bounds and discourage dose escalation, not to endorse anti-aging use. Default to the conservative band, cycle, and reassess.
Global dose bands · practice-pattern + Phase I bridge

Dose tiers for both forms & weight-band interpolation.

The engine anchors every protocol to three tiers per form — a once-weekly milligram model (DAC) and a daily microgram model (No-DAC). No-DAC weight bands default to a target of ≈ 2.7 µg/kg/day, consistent with the 200–300 µg/day practice range. All values are evidence grade D, bridged to the Phase I 30–120 µg/kg single-dose data.

BandDAC (weekly)No-DAC (daily)RationaleGrade
Low500–750 µg/week100 µg/dayConservative start / somatopause / sensitive individuals; well below the Phase I 30 µg/kg single dose.D
Standard1,000–1,500 µg/week200–300 µg/dayMost common practice band; reflects historical compounding-era guidelines for both forms.D
High ceiling2,000 µg/week300–600 µg/dayUpper end of practice ranges; Phase I studied up to 100 µg/kg with GI adverse events at that level — above this, flag as experimental.D/P

Weight-band interpolation · No-DAC daily (speculative)

Body weightLow (1.3 µg/kg/d)Standard (2.7 µg/kg/d)High (4 µg/kg/d)Round-to
~55 kg (120 lb)~72 µg~150 µg~220 µg150 µg
~65 kg (143 lb)~85 µg~175 µg~260 µg150–200 µg
~75 kg (165 lb)~100 µg~200 µg~300 µg200 µg
~85 kg (187 lb)~110 µg~230 µg~340 µg200–250 µg
~95 kg (209 lb)~125 µg~255 µg~380 µg250 µg
~105 kg (231 lb)~135 µg~285 µg~420 µg300 µg

Round to the nearest 50 µg for practical syringe measurement. The DAC weekly dose does not scale tightly with body weight in practice — most protocols use a flat 1–2 mg/week titrated to IGF-1 rather than a per-kg figure.

Titration logic · engine-ready decision rules

Escalation, hold & stop logic.

Unlike most atlas peptides, CJC-1295 has a genuinely validated pharmacodynamic governor — serum IGF-1 — so titration is anchored to a real biomarker rather than a borrowed surrogate. Escalation requires both an IGF-1 response floor and a safety floor; the IGF-1 ceiling and malignancy rules are non-editable hard stops.

Decision nodeRule templateGrade
EscalateIf time_on_therapy ≥ 4 wk AND IGF-1 still <1.5× baseline (or low-normal for age) AND no safety flags → step to next higher band (DAC +0.5–1 mg/week; No-DAC +50 µg/day).D
De-escalateWater retention / peripheral edema (≥grade 1), persistent headache (>3 d), arthralgia/myalgia, or injection-site lipodystrophy temporally linked to a dose step → reduce dose ~50% and rotate sites. GH-class effects, usually dose-dependent.D
HoldFasting glucose >126 mg/dL or HbA1c >6.5% → hold, do not restart without endocrinology review (chronic GH elevation induces insulin resistance). Carpal-tunnel symptoms → hold or de-escalate.D · (GH class B)
Hard stop · IGF-1 ceilingIGF-1 >2.5× ULN → discontinue immediately. Supraphysiological IGF-1 carries tumor-promotion risk and acromegalic potential. Non-editable.C/P
Permanent stop (hard)New or progressing malignancy on therapy; pregnancy/lactation; known pituitary tumor or active acromegaly; patient preference after disclosure. Encode as non-editable red hard-stops.C/P

Special populations — diabetes/prediabetes, active or prior malignancy, pituitary disease, pregnancy: see the contraindication table in §05. The 8-day DAC half-life means a hard-stop trigger still leaves >1 week of residual exposure — stop early and monitor through clearance.

Biomarker scaffold · IGF-1 validated, rest borrowed

Response & safety monitoring bundles.

CJC-1295 is the rare case where the primary PD marker is validated: serum IGF-1 was the pharmacodynamic endpoint in the Phase I program. The safety/metabolic markers around it, however, are imported from general GH research and flagged validated_for_CJC = false.

BiomarkerRationaleFrequencyValidated for CJC?
Serum IGF-1Primary PD marker; confirms GH-axis activation and screens for supraphysiologic elevation. Target 1.2–2.0× baseline / within age-adjusted range.Baseline → 4 wk → 8 wk → q12 wkYes · Teichman 2006
Fasting glucoseGH-mediated insulin resistance.Baseline → 4 wk → q12 wkNo (GH-extrapolated)
HbA1cChronic glycemic burden; discontinue >6.5%.Baseline → q12 wkNo
Thyroid panel (fT3/fT4/TSH)GH can alter T4→T3 conversion; hypothyroid patients may need T4 adjustment.Baseline → q12 wkNo
Serum prolactinOnly when stacking with GHRPs other than ipamorelin (e.g. GHRP-6).Baseline; if symptomsNo
Lipid panel · body compGH effects on lipids and fat/lean mass (exploratory efficacy).Baseline → 12 wkNo

Architecture note: store IGF-1 with validated_for_CJC = true and every other marker as false. Single time-point GH is unreliable (pulsatile) — IGF-1 is the surrogate of record; do not titrate on spot GH.

No-DAC daily ladder · practice-pattern · grade D

Visual titration: from initiation to washout.

Week 1–2 100µg/day · init Pre-bed, fasted · establish tolerability
Week 3–4 150µg/day · step 2 +50 µg / 2 wk · gate on tolerance
Week 5–6 200µg/day · step 3 Standard band · check IGF-1 trend
Week 7–8 200–300µg/day · maint Maintenance · ± BID split or add GHRP
Then Washout8 wk off Reassess IGF-1 & benefit · repeat cycle if clear
L2 · Reconstitution & dose math · dual-unit (µg / mg)

Reconstitution & Dose Calculator

For reference only. Not medical dosing advice. CJC-1295 runs on two unit systems — No-DAC is dosed in micrograms (µg) daily, DAC in micrograms-to-milligrams once weekly. Choose the form to set sensible defaults; the math is shown in µg with the mg equivalent. Verify purity (≥98% HPLC), sterility, endotoxin, identity (MS), and storage before any injection, and use only verified product.

Concentration
Draw volume
Units (U-100)
Doses per vial
Cadence basis
04 · Combination protocols

Stacking CJC-1295.

CJC-1295 is one of the most frequently stacked peptides in the GH-axis world — the GHRH-analog half of nearly every "GH-secretagogue" protocol. No published controlled human study has evaluated CJC-1295 in any of these combinations; the GHRH+GHRP synergy is supported by mechanistic and preclinical data, while the rest are community-derived concepts. The single most important stacking rule is an absolute contraindication, not a synergy: never combine CJC-1295 with exogenous GH or IGF-1 LR3 (see the hard-constraint note).

CJC-1295 + Ipamorelin · the standard stack
Moderate–strong (mechanistic)
CJC No-DAC 200 µg Ipamorelin 200–300 µg SC · 1–3× daily
The most-used GH-secretagogue combination. Dual-pathway synergy: CJC-1295 acts via GHRHR (Gs/cAMP/PKA) while ipamorelin acts via GHSR1a (Gq/IP3/Ca²⁺) and suppresses somatostatin tone — combined GH release is 2–5× either agent alone. Ipamorelin uniquely does not raise cortisol or prolactin, making it the preferred GHRP partner. Engine default: keep each component at its saturation dose (≈200–300 µg) rather than pushing one component high.
ComponentPrimary mechanismEvidence
CJC-1295GHRHR agonism · pulse ceiling ↑Phase I human (B)
IpamorelinGHSR1a agonism · somatostatin ↓Phase I / preclinical (B/C)
CombinationComplementary pituitary pathways · 2–5× GHMechanistic · no combo RCT (C/D)
CJC-1295 + GHRP-6 · larger pulse, more side effects
Moderate (preclinical)
CJC DAC 1–2 mg/wk GHRP-6 100–300 µg ×2–3/day SC · aggressive
GHRP-6 produces larger GH pulses than ipamorelin but also stimulates appetite strongly (ghrelin pathway) and can raise cortisol and prolactin. In preclinical models, GHRP-6 + CJC-1295 DAC significantly increased GH/IGF-1 without raising prolactin versus GHRP-6 alone. Less preferred than the ipamorelin stack for most clinical contexts; not suitable for obesity/metabolic syndrome without supervision because of the hunger effect.
ComponentRoleStatus
CJC-1295 DACSustained GHRH baselinePhase I human (B)
GHRP-6Ghrelin-receptor pulse · appetite ↑Preclinical / practice (C/D)
CombinationBaseline + large pulseAnimal synergy data (C)
CJC-1295 + BPC-157 · "recovery" stack
Exploratory
CJC per protocol BPC-157 250–500 µg/day repair + GH axis
Complementary, non-overlapping mechanisms — CJC-1295 drives the GH/IGF-1 anabolic axis while BPC-157 promotes local tissue repair via VEGFR2 angiogenesis and tendon/gut healing. No combination trial data exist. The pairing is mechanistically plausible (systemic anabolism + local repair) but entirely speculative; both are unapproved, and additive IGF-1 + growth-factor signaling may amplify the theoretical cancer caution. Keep both mid-range and monitor for fluid retention.
ComponentRoleStatus
CJC-1295GH / IGF-1 anabolic axisPhase I human (B)
BPC-157Angiogenesis · tissue repairPreclinical (P)
CombinationSystemic + local recoveryNo data (D)
CJC-1295 + MK-677 (Ibutamoren)
Exploratory · monitor
CJC DAC 1 mg/wk MK-677 10–25 mg oral PM GH-axis stacking
MK-677 is an oral ghrelin mimetic providing sustained 24-h GHSR1a stimulation; layering CJC-1295's GHRHR pulses on top may reduce injection frequency. No interaction data exist. Engine default: cap CJC at the standard band and add monitoring — MK-677 causes significant water retention, insulin resistance, and appetite increase, and stacking amplifies these metabolic effects. Not recommended for metabolically compromised patients.
ComponentMechanismAdded monitoring
CJC-1295GHRHR pulse amplificationIGF-1 · standard panel
MK-677Oral GHSR1a · 24-h toneEdema · fasting glucose · HbA1c
Hard constraint — absolute contraindications

Never stack with exogenous GH or IGF-1 LR3. Combining CJC-1295 (which already elevates endogenous GH and IGF-1) with recombinant GH or IGF-1 LR3 stacks supraphysiological IGF-1 on supraphysiological IGF-1, dramatically amplifying the theoretical tumor-promotion risk via IGF1R → PI3K/Akt → mTOR and risking acromegalic change with chronic use. This combination has no clinical rationale and clear harm potential. Never use with active or recent malignancy. Higher serum IGF-1 is an established risk factor for several cancers (prostate, breast, colorectal) in large prospective cohorts; CJC-1295 elevates IGF-1 for 9–28 days per dose — a prolonged growth-signaling window contraindicated in oncology patients. If a user profile flags active malignancy, the engine should suppress all GH/IGF-1-elevating agents and label the combination "discouraged."

05 · Safety profile & contraindications

Well tolerated short-term; long-term unknown.

CJC-1295's safety picture is better-characterized than most research peptides — but only over weeks. Phase I (single doses 30–120 µg/kg) reported no serious adverse events at 30–60 µg/kg, with mainly GI events at the 100 µg/kg ceiling. The one Phase II trial (HIV lipodystrophy, n=192 enrolled) was halted in July 2006 after a participant death — adjudicated as unrelated to drug and attributed to pre-existing coronary artery disease — and development stopped regardless. The dominant concerns are mechanistic: GH-driven insulin resistance and, over the long term, IGF-1-mediated tumor-promotion risk. No human data beyond ~12 weeks exist.

Observed / Reported AE Profile (Phase I + practice-pattern)
No serious AEs at 30–60 µg/kgAcross the Phase I ascending-dose trials, single doses of 30–60 µg/kg were safe and relatively well tolerated; no serious adverse reactions were reported.
Injection-site reactionsPain, redness, or swelling at SC sites in ~10–15% of trial exposures — generally mild–moderate and self-limited. Rotate sites.
Water retention / peripheral edemaA GH-class effect; mild–moderate, dose-dependent. With the DAC form it persists >1 week after the last dose. De-escalate if ≥grade 1.
Headache, flushing, dizziness, nauseaMild and occasional in trial data; nausea and GI events clustered mainly at the 100 µg/kg single-dose ceiling.
Carpal tunnel / arthralgiaGH-mediated soft-tissue edema can compress the median nerve — a recognized GH class effect, usually dose-dependent and reversible on de-escalation.
Theoretical & Unresolved Risks
Tumor promotion (IGF-1)IGF-1 activates IGF1R → PI3K/Akt and MAPK/ERK — established pro-proliferative, anti-apoptotic pathways. Elevated IGF-1 is an epidemiological risk factor for colorectal, prostate, and breast cancer. CJC-1295 sustains IGF-1 elevation 9–28 days per dose — the central long-term concern.
Insulin resistance / hyperglycemiaGH is counter-regulatory to insulin; sustained (vs pulsatile) elevation worsens glucose handling. Monitor fasting glucose/HbA1c; hold if hyperglycemic.
Acromegalic change (chronic)Theoretically possible with chronic supraphysiologic GH/IGF-1; not seen in short trials but a real concern with indefinite use.
Pituitary desensitizationA theoretical concern with the DAC form's sustained stimulation; preserved pulsatility in human sampling argues against it short-term, but long-term data are absent.
Antibody formationNot reported in CJC-1295 trials but theoretically possible with any exogenous peptide; uncharacterized at scale.
Product quality / contaminationAs an unapproved "research chemical," sequence-error and endotoxin contamination are a substantial practical hazard. Require HPLC ≥98%, sterility, endotoxin limits, and MS identity.
Long-term safety (absent)No human data beyond ~12 weeks, and development was abandoned in 2007 — the single largest unknown.

Contraindication reference

Some contraindications here are mechanistically grounded (IGF-1/cancer, GH/glucose) rather than purely precautionary, given the GH-axis pharmacology — but none are derived from controlled CJC-1295 outcome data.

Condition / factor Risk level Applies to Rationale
Active malignancy (any type)AvoidAll routesIGF-1 elevation promotes tumor proliferation via IGF1R/PI3K-Akt. Absolute contraindication.
History of malignancy (<5 yr)AvoidAll routesResidual tumor cells may respond to IGF-1 growth signaling.
Pituitary tumor / hyperfunctionAvoidAll routesDirect GHRHR stimulation may exacerbate tumor activity; acromegaly history likewise.
Pregnancy / breastfeedingAvoidAll routesUnknown effects on fetal/neonatal GH axis; no safety data.
Diabetes mellitus (T1 / T2)Specialist onlySystemicGH-mediated insulin resistance worsens glycemic control; use only with endocrinology oversight.
Prediabetes (IFG / IGT)CautionSystemicRisk of progression to T2DM with chronic GH elevation.
Competitive athlete / WADA poolAvoidAll routesProhibited under WADA S2, in- and out-of-competition — use is a doping violation regardless of safety.
Active cardiovascular diseaseCautionSystemicGH-mediated fluid retention increases cardiac preload.
Severe hepatic / renal impairmentCautionSystemicAltered clearance and IGF-1 metabolism; no stratified PK data.
Unverified "research-chemical" productAvoidAll routesSequence-error and endotoxin contamination are a dominant practical risk; require HPLC ≥98%, sterility, endotoxin, MS identity.

Suggested monitoring for CJC-1295 research protocols

Baseline

Serum IGF-1 (the validated PD marker), fasting glucose, HbA1c, CMP (LFTs/renal), CBC, lipid panel, thyroid panel; pregnancy test if reproductive potential; malignancy screen / history review. Body composition (DEXA/bioimpedance) if tracking efficacy.

Week 4

IGF-1 (escalation gate: <1.5× baseline → consider step-up; >2.5× ULN → hard stop), fasting glucose. Tolerability review: edema, headache, paresthesia, injection-site.

Week 12 (q12 wk)

IGF-1, fasting glucose/HbA1c, thyroid, lipids; body composition if tracked. Decision: continue, escalate, hold, or step back per titration logic.

End of cycle

Repeat IGF-1 + safety panel. Document objective and subjective outcomes for cycle-to-cycle comparison. Decision: washout, resume, modify, or discontinue.

Washout / reassess

For the DAC form allow ≥2 weeks of clearance before interpreting an off-cycle IGF-1 (8-day half-life). Confirm IGF-1 returns toward baseline; reassess benefit before any further cycle.

Stop / hold criteria (hard)

IGF-1 >2.5× ULN; new malignancy diagnosis or progression; pregnancy; fasting glucose >126 mg/dL or HbA1c >6.5% (hold); carpal-tunnel symptoms; any new diagnosis changing the risk/benefit calculus.

06 · Key studies & research program

Solid Phase I PK/PD, no Phase III.

CJC-1295's evidence base is the inverse of most atlas peptides: a genuine, published, placebo-controlled human PK/PD program — but an abandoned one. Three published human studies (~n=33 with complete data) plus one halted Phase II (n=192 enrolled, unpublished) constitute the entire human record. The GH/IGF-1 elevation is reproducible and dose-dependent; what is missing is any evidence that this surrogate translates into a clinical outcome.

Phase I RCT · 2006
n=21
Teichman et al. (JCEM) — two placebo-controlled double-blind ascending-dose trials (28 d & 49 d). GH ↑2–10× ≥6 d; IGF-1 ↑1.5–3× 9–11 d; t½ 5.8–8.1 d; IGF-1 up to 28 d on repeat dosing. PMID 16352683.
Human · 2006
n=12
Ionescu & Frohman (JCEM) — pulsatile GH persists during continuous CJC-1295 stimulation; trough GH and IGF-1 elevated; well tolerated. PMID 17018654.
Proteomics · 2009
subset
Sackmann-Sala et al. (Growth Horm IGF Res) — serum protein-profile changes downstream of GH/IGF-1 activation in a subset of the Teichman cohort. PMID 19386527.
Phase II · halted
n=192
NCT00267527 — HIV-lipodystrophy, randomized placebo-controlled. Halted July 2006 after a participant death (adjudicated unrelated; CAD). Results never published; development stopped.
B Phase I · pivotal PK/PD

Teichman et al. 2006 — pivotal human PK/PD program

Two randomized, placebo-controlled, double-blind, ascending-dose trials (durations 28 and 49 d) in 21 healthy adults aged 21–61. Single SC doses produced dose-dependent 2–10× GH (≥6 d) and 1.5–3× IGF-1 (9–11 d) elevation; estimated half-life 5.8–8.1 d; multiple doses kept IGF-1 above baseline up to 28 d with a cumulative effect; no serious adverse reactions; well tolerated particularly at 30–60 µg/kg. The single strongest human dataset for any GHRH analog in this atlas.

B Human · pulsatility

Ionescu & Frohman 2006 — pulsatility preserved

Demonstrated that pulsatile GH secretion persists during continuous stimulation by CJC-1295 — endogenous somatostatin continues to brake GH release, so trough and mean GH rise while the peak-to-trough rhythm is maintained. This is the mechanistic distinction from exogenous rhGH and the headline safety argument for GHRH analogs (JCEM 2006;91(12):4792-7).

C Mechanism · originator

Robinson/ConjuChem 2005 — DAC:GRF identification

The originator study (Endocrinology 2005;146(7):3052-8) showed that hGRF(1-29)–albumin bioconjugates activate the GRF receptor on the rat anterior pituitary and identified CJC-1295 as the long-lasting lead analog — the foundational work behind the DAC albumin-binding strategy (PMID 15817669).

C Animal · proof of concept

Alba et al. 2006 — GHRH-knockout mouse

Once-daily CJC-1295 normalized growth, body composition, and metabolic function in the GHRH-knockout mouse — restoring body weight, length, femur/tibia length and lean mass, and increasing pituitary GH mRNA and somatotroph proliferation over 5 weeks (Am J Physiol Endocrinol Metab 2006;291(6):E1290-4, PMID 16822960). The cleanest in-vivo proof of concept for the molecule.

B Epidemiology · IGF-1 risk

IGF-1 & cancer — large prospective cohort

A prospective cohort of roughly 400,000 participants confirmed that higher serum IGF-1 is a risk factor for several cancers (including colorectal, prostate, and breast) over multi-year follow-up. Mechanistically, IGF-1 promotes malignant transformation, growth, invasion and metastasis via IGF1R/MAPK/PI3K-Akt (review). Indirect to CJC-1295, but the basis for the prolonged-IGF-1-elevation oncology caution.

D Program · discontinued

Development history & the halted Phase II

ConjuChem's Phase II HIV-lipodystrophy trial (NCT00267527, n=192 enrolled) was halted in July 2006 after a participant death adjudicated as unrelated to drug (pre-existing coronary artery disease); results were never published. Both the Phase I GH-deficiency and Phase II lipodystrophy programs were discontinued in March 2007. No registered CJC-1295 efficacy trial is active as of 2026.

GRADE summary

Overall evidence strength is LOW–MODERATE, and crucially biomarker-only. CJC-1295 has robust Phase I PK/PD evidence — GH and IGF-1 elevation are reproducible and dose-dependent (grade B) — but no Phase III, no completed Phase II (the only one was halted for an unrelated death and never published), and no evidence for any clinical outcome (body composition, GH-deficiency treatment, lipodystrophy reversal). GH/IGF-1 elevation is a surrogate, not a demonstrated benefit. Long-term human safety beyond ~12 weeks is absent. What is missing: Phase III efficacy trials, long-term safety follow-up, head-to-head vs tesamorelin/sermorelin, and combination-protocol RCTs. This is why the dosing engine above is framed as a speculative hypothesis layer, not a guideline.

CJC-1295 vs. the GH-secretagogue family

ParameterCJC-1295 (DAC)Tesamorelin (Egrifta SV)Sermorelin (GHRH 1-29)Ipamorelin
Mechanism classGHRH analog (GHRHR agonist)GHRH analog (GHRHR agonist)GHRH analog (GHRHR agonist)GHRP / ghrelin-receptor (GHSR1a) agonist
Half-life5.8–8.1 days (DAC)26–38 minutes~5–10 minutes~2 hours
Dosing frequencyOnce weekly (DAC)Daily SCDaily / nightly SC1–3× daily (with a GHRH analog)
Evidence tierPhase I/II (B) · no Phase IIIPhase III RCT (A) · FDA-approvedPhase II (B) · FDA-approved (GHD)Phase I / preclinical (B/C)
FDA statusUnapproved · developmental drug · not 503AApproved (NDA 022505) · 503A-compoundableApproved (GHD) · 503A-compoundableUnapproved · regulatory limbo
WADA statusProhibited (S2)Prohibited (S2)Prohibited (S2)Prohibited (S2)
Distinguishing featureLongest t½ (8 d); once-weekly; abandoned developmentOnly FDA-approved GHRH analog; visceral-fat RCT dataClosest to native GHRH; most physiologic pulsatilitySelective GHRP; no cortisol/prolactin; the standard CJC partner
07 · Compare & contrast

Adjacent peptides.

08 · Evidence & references

Every claim, graded and sourced.

A · RCT / meta-analysis
B · Large cohort / consistent trial set
C · Small trial / mechanistic
P · Preclinical / animal
D · Expert / textbook / regulatory
Explore the ATLAS index

More GH Axis peptides & tools.